![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
With this acquisition, Lodo expands its preclinical pipeline with selective proteasome inhibitors with potential application in solid tumor cancers and other indications. Logo gains exclusive license to intellectual property from university of california.
Lead Product(s): TIR-199
Therapeutic Area: Oncology Product Name: LODO-141
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Lodo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 03, 2020